Intellia Therapeutics, Inc. Contracts & Agreements
53 Contracts & Agreements
- Business Finance (14 contracts)
- Business Operations (7)
- Human Resources (10)
- Intellectual Property (12)
- Real Estate (6)
- Uncategorized (4)
- Third Amendment to License and Collaboration Agreement by and between Registrant and Regeneron Pharmaceuticals, Inc., dated September 29, 2023 (Filed With SEC on November 9, 2023)
- Letter Agreement (Second Amendment) to License and Collaboration Agreement by and between Registrant and Regeneron Pharmaceuticals, Inc., dated November 22, 2022 (Filed With SEC on November 9, 2023)
- Amendment to Lease Agreement by and between the Registrant and Are-Winter Street Property, LLC, dated as of June 20, 2023 (Filed With SEC on August 3, 2023)
- Underwriting Agreement, dated as of November 30, 2022, by and between the Company and Goldman Sachs & Co. LLC (Filed With SEC on December 1, 2022)
- Amended and Restated Corporate Bonus Plan (Filed With SEC on August 4, 2022)
- Retirement Policy for Equity Awards (Filed With SEC on August 4, 2022)
- Consent to Assignments, Licensing and Common Ownership and Invention Management Agreement dated December 15, 2016 by and between the Registrant, CRISPR Therapeutics AG, The... (Filed With SEC on February 24, 2022)
- Underwriting Agreement, dated as of June 29, 2021, by and among the Company and Goldman Sachs & Co LLC, Jefferies LLC, SVB Leerink LLC, and Barclays Capital Inc., as... (Filed With SEC on July 2, 2021)
- Amendment #3 to License and Collaborative Research Agreement, dated as of June 14, 2021, by and between Novartis and Intellia (Filed With SEC on June 17, 2021)
- License Agreement dated as of July 16, 2014 by and between Registrant (as successor in interest of Intellia Therapeutics, LLC) and Caribou Biosciences, Inc (Filed With SEC on May 6, 2021)
- License and Collaborative Research Agreement dated as of December 18, 2014 by and between Registrant and Novartis Institutes for BioMedical Research, Inc (Filed With SEC on May 6, 2021)
- Fourth Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 6, 2021)
- Third Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 26, 2021)
- Underwriting Agreement, dated as of December 1, 2020, by and among the Company and Goldman Sachs & Co LLC, Jefferies LLC, and SVB Leerink LLC, as representatives of the several... (Filed With SEC on December 2, 2020)
- Corporate Bonus Plan, effective April 3, 2020 (Filed With SEC on August 6, 2020)
- Underwriting Agreement, dated as of June 2, 2020, by and among the Company and Goldman Sachs & Co. LLC, Jefferies LLC, and SVB Leerink LLC, as representatives of the several... (Filed With SEC on June 3, 2020)
- Amendment No. 1, dated May 30, 2020, to the License and Collaboration Agreement, dated April 11, 2016, by and between Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc (Filed With SEC on June 1, 2020)
- Stock Purchase Agreement, dated May 30, 2020, by and between Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc (Filed With SEC on June 1, 2020)
- Lease, dated as of March 12, 2020, by and between the Company and 281-295 Albany Street Leasehold LLC (Filed With SEC on May 7, 2020)
- Second Amendment to Lease, dated as of March 12, 2020, by and between the Company and MIT 130 Brookline Leasehold LLC (Filed With SEC on May 7, 2020)
- Second Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on February 27, 2020)
- Description of Certain Registrants Securities (Filed With SEC on February 27, 2020)
- First Amendment to Lease, dated as of April 5, 2019, by and between the Company and MIT 130 Brookline Leasehold LLC (Filed With SEC on May 2, 2019)
- Agreement and Amendment to License and Collaborative Research Agreement, dated as of December 3, 2018, by and between Novartis and the Company (Filed With SEC on February 27, 2019)
- Form of Amended and Restated Employment Agreement (Filed With SEC on April 17, 2018)
- Underwriting Agreement, dated as of November 1, 2017, by and among the Company and Credit Suisse Securities (USA) LLC, Jefferies LLC, and Leerink Partners LLC, as representatives... (Filed With SEC on November 3, 2017)
- [***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE... (Filed With SEC on December 16, 2016)
- Signature(s)Guaranteed: Medallion Guarantee Stamp (Filed With SEC on May 17, 2016)
- License and Collaborative Research Agreement (Filed With SEC on May 5, 2016)
- LICENSE ANDCOLLABORATION AGREEMENT By and Between REGENERON PHARMACEUTICALS, INC. and INTELLIATHERAPEUTICS, INC. April 11, 2016 (Filed With SEC on May 5, 2016)
- INTELLIA THERAPEUTICS, INC. AMENDED AND RESTATED 2015 STOCK OPTION AND INCENTIVE PLAN (Filed With SEC on April 27, 2016)
- INDEMNIFICATION AGREEMENT (Filed With SEC on April 27, 2016)
- INTELLIA THERAPEUTICS, INC. 2016 EMPLOYEE STOCK PURCHASE PLAN (Filed With SEC on April 27, 2016)
- LICENSE ANDCOLLABORATION AGREEMENT By and Between REGENERON PHARMACEUTICALS, INC. and INTELLIATHERAPEUTICS, INC. April 11, 2016 (Filed With SEC on April 27, 2016)
- COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on April 27, 2016)
- COMMON STOCK PURCHASE AGREEMENT (Filed With SEC on April 27, 2016)
- EMPLOYMENT AGREEMENT (Filed With SEC on April 27, 2016)
- Shares INTELLIATHERAPEUTICS, INC. Common Stock UNDERWRITING AGREEMENT (Filed With SEC on April 27, 2016)
- AMENDMENT NO. 2 TO INVESTORS RIGHTS AGREEMENT (Filed With SEC on April 27, 2016)
- License and Collaborative Research Agreement (Filed With SEC on April 19, 2016)
- LICENSEAGREEMENT (Filed With SEC on April 19, 2016)
- SERVICESAGREEMENT (Filed With SEC on April 19, 2016)
- AMENDMENT NO. 1 TO INVESTORS RIGHTS AGREEMENT (Filed With SEC on April 12, 2016)
- LICENSE ANDCOLLABORATION AGREEMENT By and Between REGENERON PHARMACEUTICALS, INC. and INTELLIATHERAPEUTICS, INC. April 11, 2016 (Filed With SEC on April 12, 2016)
- License and Collaborative Research Agreement (Filed With SEC on April 11, 2016)
- 130 BROOKLINE STREET CAMBRIDGE, MASSACHUSETTS LEASE SUMMARY SHEET (Filed With SEC on April 11, 2016)
- LEASE by and between BMR-SIDNEYRESEARCH CAMPUS LLC, a Delaware limited liability company and INTELLIA THERAPEUTICS, INC., a Delaware corporation Table of Contents (Filed With SEC on April 11, 2016)
- AMENDMENT NO. 1 TO LICENSE AGREEMENT (Filed With SEC on April 11, 2016)
- ADDENDUM TO LICENSE AGREEMENT (Filed With SEC on April 11, 2016)
- SERVICESAGREEMENT (Filed With SEC on April 11, 2016)
- LICENSEAGREEMENT (Filed With SEC on April 11, 2016)
- INTELLIA THERAPEUTICS, INC. SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN (Filed With SEC on April 11, 2016)
- INVESTORS RIGHTS AGREEMENT (Filed With SEC on April 11, 2016)